FDA Approvals in NSCLC and Soft Tissue Sarcoma, Priority Review in Bladder Cancer, and More

Justin Gallagher reports two FDA approvals for immunotherapy in lung cancer, an approval in soft tissue sarcoma, a priority review designation in bladder cancer, an updated indication for a drug in prostate cancer, encouraging phase III results in bladder cancer, noninferiority findings in multiple myeloma, and a European approval in pancreatic cancer.

• 类别